Lilly Knocks On Wood: Transition of Zyprexa Dual Eligibles Moves Along Smoothly
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly says that it is not hearing any "anecdotal stories" regarding troubles with transitioning dual eligibles taking the atypical antipsychotic to Medicare.
You may also be interested in...
Zyprexa Could Gain From CATIE Cost/Benefit Analysis, Lilly Says
Forthcoming cost-effectiveness analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness study could prove to be a boon for Zyprexa because of reduced hospitalization with Lilly’s atypical antipsychotic.
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency